1/This is an excellent example of WHY @NIH needs to change their gender violence policies. Not only was this researcher found to be responsible by civil legal standards for sexually harassing a post-doc, the uni. found him resp. for creating a hostile environment. #metoostem
2/Literally the DAY the sexual harassment settlement was reached on September 17, 2018 the university publishes a letter lauding this researcher for obtaining a $20 million grant from @NIH: bit.ly/2P97QsW#MeTooSTEM
3/ What happened to this researcher? He has to take a training on sexual harassment and might have a letter put into his HR file. He is still the director of an institute. What happened to the post-doc? She has left the university and her research has not been published.
3/ Culture. "I still don’t think that the prospect of being sexually assaulted was as bad as watching the next generation of sexual harassers being formed. I think that was the worst part for me." (Nontenure-track faculty) #MeToo#MeTooSTEM#womeinmedicine#MedEd#heforshe
2/Although CMS requires Part D formularies to include OUD treatment, and mandate Part C Medicare Advantage to cover behav health services related to addiction services, the only FDA approved OAT meeting the Part D definition is bupe/naloxone
3/Further, if bupe/naloxone is administered in an OTP it will not be reimbursed, because an OTP is not a pharmacy, a reimbursement requirement for Part D. Same issue for methadone. Methadone is required to be OTP administered (42 CFR 8.12) it is not a qualified Part D product.
2/ Title IX. This article is missing information about federally mandated reporting processes and protections that legally protect medical students (and all students in the U.S.).
3/Anecdotal beliefs perpetuate harms. A physician expert states “the trainee must amass allies before lodging this complaint…” This is legally incorrect, a single report is enough to trigger Title IX and this reinforces the notion that single reports will not be believed.